Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared on X about a recent paper by Y.-W. Zhou et al. published on ESMO Open:
“New in ESMO Open (2025):
Neoadjuvant FOLFOXIRI in high-risk locally advanced colon cancer (phase II)
72 patients (T4/N2, median age 53)
Outcomes after 4 cycles:
- 86.9% TRG 0–2
- 100% R0 resection
- 17.2% 2-yr recurrence
- 51.4% grade 3–4 AEs (hematologic)
- 1 treatment-related death
Why it matters:
- Beyond FOxTROT: in a cohort dominated by T4/N2, triplet chemo achieved striking downstaging and resection rates.
Caveats:
- Single-arm, non-randomized design → not confirmatory
- Relatively young cohort (median 53) may overestimate tolerability
- dMMR subgroup not aligned with current immunotherapy standards
Takeaway:
- FOLFOXIRI shows promise for high-risk colon cancer, but phase III trials are needed.”
Title: Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: a single-arm phase II trial
Authors: Y.-W. Zhou, G.-X. Wei, X.-R. Chen, P. Cao, M.-T. Wei, C. Fang, X.-B. Deng, L. Li, C. Wang, Y. Shu, Z.-Q. Wang, Y.-Y. Yu, W.-J. Meng, M. Qiu
More posts featuring Galip Can Uyar.
